The EEF2K Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population featuring targeted disruption of the EEF2K gene in the NCI-H1299 non-small cell lung carcinoma cell line. This heterogeneous pool provides a loss-of-function model for eukaryotic elongation factor 2 kinase (EEF2K) studies, avoiding clonal artifacts and preserving genetic diversity for population-level functional assays.
NCI-H1299 cells are a widely used model of lung adenocarcinoma metastasis, originally derived from a lymph node metastasis of a non-small cell lung carcinoma. These cells are p53-deficient, contributing to their aggressive tumorigenic phenotype, high proliferative capacity, invasive potential, and apoptosis resistance. The p53-null background makes them particularly suitable for investigating molecular drivers of lung cancer progression and drug resistance.
EEF2K encodes a calcium/calmodulin-dependent kinase that phosphorylates and inhibits eukaryotic elongation factor 2 (eEF2), a central regulator of translation elongation. Its activity is tightly controlled: activated by the Ca2?/calmodulin complex and AMPK under nutrient deprivation or energy stress, and inhibited by mTORC1 and RSK (downstream of MAPK/ERK) during growth-promoting conditions. Upon activation, EEF2K phosphorylates eEF2 at Thr56, reducing ribosome affinity and slowing peptide elongation to conserve energy and modulate protein synthesis, thus integrating metabolic and stress signals at the level of translation.
In the NCI-H1299 context, EEF2K knockout is especially informative for dissecting interactions between translation control, metabolic adaptation, and oncogenic signaling. The p53 deficiency creates genomic instability and altered stress responses, where EEF2K may serve a compensatory pro-survival role. Disruption of EEF2K allows interrogation of its contributions to autophagy regulation, chemotherapy resistance, and metabolic reprogramming, while the mTOR and AMPK pathway connections enable detailed analysis of translation-dependent mechanisms driving NSCLC aggressiveness and metastasis.
Research applications include studying EEF2K in lung cancer biology, assessing it as a therapeutic target, and unraveling chemoresistance mechanisms to agents such as cisplatin and paclitaxel. These polyclonal knockout cells are suitable for western blotting (EEF2K, phospho-eEF2), proliferation (MTT/BrdU), apoptosis (annexin V), migration/invasion (Transwell), drug sensitivity, autophagy (LC3 immunoblot/fluorescence), polysome profiling, RNA-seq, RT-qPCR, and phospho-signaling analysis focusing on mTOR, AMPK, and RSK. For further information or custom inquiries, please contact Ascent Research.
